Status: Recruiting
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).
Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: MiNK TherapeuticsUpdated: Jun 26, 2026Locations: 4
Eligibility criteria
Admission to an intensive care unit (ICU) with severe pneumonia of any etiology... [+3]
More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters... [+3]